The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Tumor-associated CD66b+ MDSCs in WM and their impact on T-cell immune function
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the role of myeloid-derived suppressor cells (MDSCs) in Waldenström’s macroglobulinemia (WM), and their impact on patient immune response. Prof. Ansell further explains the increase in MDSCs seen in the bone marrow of patients with WM, and the possibility of using these as a therapeutic target. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.
